Methods And Compositions For Oral Administration Of Proteins
A composition and protein technology, applied in the direction of peptide/protein composition, drug combination, drug delivery, etc., can solve the problems of fat hyperplasia, lipodystrophy, atrophy, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0124] implement Example 1: Oral formulations of insulin, SNAC, and protease inhibitors
[0125] Material and experimental methods
[0126] preparation
[0127] Prepare the following preparations: (1) containing 6mg insulin, 250mg SNAC, 125mg SBTI, (2) containing 6mg insulin, 250mg SNAC, 2.5mg aprotinin, 125mg SBTI, (3) containing 6mg insulin, 250mg SNAC, 2.5mg aprotinin Peptide, 125mg SBTI, (4) with 6mg insulin, 250mg SNAC. The formulations were stored in the refrigerator (4°C) prior to dosing.
[0128] result
[0129] In a subsequent experiment, the formulations described in the "Formulations" section were orally administered to 3 healthy human subjects. like figure 1 As shown, blood glucose levels were significantly lower and more stable in human subjects treated with formulations (1) and (3). These results indicate that formulations comprising a combination of protease inhibitors and SNAC are superior to formulations comprising SNAC alone. Specifically, the co...
Embodiment 2
[0132] Example 2: Optimization of Omega-3 Fatty Acid Sources
[0133] Various omega-3 fatty acids or sources of omega-3 fatty acids, such as those listed above in this specification, were compared for their ability to protect insulin following oral administration in the methods and compositions of the invention. Insulin tablets or capsules were formulated as described in the previous examples, except that the insulin was dissolved in an alternative source instead of fish oil. The most effective source of omega-3 fatty acids is used in the examples that follow.
Embodiment 3
[0134] Example 3: Optimization of Protease Inhibitors
[0135]Various protease inhibitors (either non-toxic or having an acceptable toxicity profile; such as those listed above in this specification) were compared for their ability to protect insulin following oral administration in the methods and compositions of the invention. Insulin and / or exenatide tablets or capsules are formulated as described in the above examples, except that alternative protease inhibitors are used in place of SBTI and / or aprotinin. The amount of protease inhibitors was also varied to determine the optimal amount. The most effective protease inhibitors / amounts were used in subsequent examples.
PUM
| Property | Measurement | Unit |
|---|---|---|
| Molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 